Sam Jackson joined Neuron23 in 2022. A strategic leader and clinical development expert, Sam is a board-certified emergency physician with fellowship training in medical toxicology. He has a long history of successful leadership experience in the biopharmaceutical industry.
Before joining Neuron23, Sam served as Senior Vice President of Clinical Development at Alector, where he oversaw clinical development and operations while leading programs in Alzheimer’s disease and frontotemporal dementia. Sam led the clinical due-diligence discussions that resulted in a transformational alliance with GlaxoSmithKline in one of the largest deals in the neurodegeneration space. He also served as interim Chief Medical Officer of Alector for seven months.
Prior to Alector, Sam held roles of increasing responsibility at Amgen, Genentech, Dynavax and Alkahest. At Dynavax, Sam ran a pivotal Phase 3 trial and was part of the small team that filed the BLA resulting in approval of a novel vaccine for Hepatitis B. At Alkahest, he served as Chief Medical Officer, where he helped build the clinical organization and designed and initiated four phase 2 trials in neurologic and ophthalmologic diseases.
Sam graduated from Stanford University and received his MD and MBA degrees from the University of Pennsylvania.
Before joining Neuron23, Sam served as Senior Vice President of Clinical Development at Alector, where he oversaw clinical development and operations while leading programs in Alzheimer’s disease and frontotemporal dementia. Sam led the clinical due-diligence discussions that resulted in a transformational alliance with GlaxoSmithKline in one of the largest deals in the neurodegeneration space. He also served as interim Chief Medical Officer of Alector for seven months.
Prior to Alector, Sam held roles of increasing responsibility at Amgen, Genentech, Dynavax and Alkahest. At Dynavax, Sam ran a pivotal Phase 3 trial and was part of the small team that filed the BLA resulting in approval of a novel vaccine for Hepatitis B. At Alkahest, he served as Chief Medical Officer, where he helped build the clinical organization and designed and initiated four phase 2 trials in neurologic and ophthalmologic diseases.
Sam graduated from Stanford University and received his MD and MBA degrees from the University of Pennsylvania.
Speaking In
4:15 PM - 5:15 PM
Wednesday, June 7
